Kim Sunkyu,Doshi Shivang,Haas Kristy,Kovats Steven,Huang Alan Xizhong,Chen Yan
申请号：
NZ71905012
公开号：
NZ719050A
申请日:
2012.07.02
申请国别(地区):
NZ
年份:
2017
代理人:
摘要：
Provided is a combination of a cyclin dependent kinase 4 or cyclin dependent kinase 6 (CDK4/6) inhibitor and a phosphatidylinositol 3-kinase (PI3K) inhibitor useful for the treatment of cancer. A preferred CDK4/6 inhibitor is a compound of Formula A (7-Cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide) (ribociclib). Preferred PI3K inhibitors are the compounds of Formula B1 (5-(2,6-di-4-morpholinyl-4-pyrimidinyl)-4-(trifluoromethyl)-2-pyrimidinamine) (buparlisib) and Formula B2 ((S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({ 4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl} -amide)) (alpelisib).
